Penny stock below Rs 10 locked in upper circuit after Board announced record date for 1:1 bonus share & 1:10 stock split
DSIJ Intelligence-1 / 08 Oct 2025/ Categories: Bonus and Spilt Shares, Penny Stocks, Trending
The stock is up by 32.5 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 242 per cent in 5 years.
On Wednesday, shares of Welcure Drugs & Pharmaceuticals Ltd hit a 5 per cent Upper Circuit to Rs 6.97 per share from its previous closing of Rs 6.64 per share.
The Board of Directors of Welcure Drugs & Pharmaceuticals Limited consider two key proposals: a stock split of equity shares in a 1:10 ratio (one equity share into ten) and the issue of bonus shares up to a 1:1 ratio (one bonus share for every one held). These actions aim to boost the company's liquidity, expand its shareholding base and make shares more affordable for investors. The Board fixed the record for bonus shares & stock split as Thursday, October 16, 2025.
Earlier, the company signed a Letter of Intent (LOI) with Telexcell Trade PTE LTD, a Singapore-based company, for a strategic all-cash equity investment. The LOI indicates Telexcell's intention to acquire up to a 25 per cent stake in Welcure at an indicative price of Rs 20 per share, which is a significant premium over the current market price. To facilitate this and other foreign investment, Welcure is also seeking shareholder approval to increase the total shareholding limit for Foreign Portfolio Investors (FPIs) and Foreign Institutional Investors (FIIs) to 49 per cent. Additionally, the company plans to raise up to Rs 80 crore through a Qualified Institutions Placement (QIP) by issuing new equity shares.
About the Company
Welcure Drugs & Pharmaceuticals Ltd, established in 1992, historically specialised in manufacturing and marketing a diverse range of pharmaceutical formulations, including tablets, capsules and dry syrups. Their extensive product portfolio covered various therapeutic categories like antibiotics, vitamins, analgesics and anti-diabetics, serving both Indian and international markets. With a recent strategic shift and improved financial performance, Welcure Drugs & Pharmaceuticals Ltd is now focused on achieving long-term sustainable growth.
The company reported a substantial financial upturn for the quarter ending June 30, 2025. Net profit soared to Rs 23.29 crore, an impressive 830 per cent increase quarter-on-quarter from Rs 2.5 crore in Q4FY25 and a significant recovery from a Rs 0.34 crore loss in Q1FY25. Revenue from operations dramatically rose to Rs 299.91 crore, nearly 1,300 per cent higher than Q4FY25's Rs 21.21 crore. The company has a market cap of Rs 78.42 crore. The stock is up by 32.5 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 242 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.